Felicitex Therapeutics Inc.

Our unique scientific platform is rooted in the biological systems that govern acquired resistance: pathways that control cellular dormancy and can be “hijacked” by cancers to enable their growth, survival, dissemination throughout the body, and evasion of current standard-of-care therapies. Felicitex has designed the first in class small molecules that inhibit DYRK1 family kinases to selectively disrupt dormant cancer cells in a manner that is tuned to disease and tissue context. This pioneering approach is lethal to cancer cells that rely on dysregulation of the cell cycle for survival and lead to the reversal of drug tolerance mechanisms, and loss of oncogene pathway addiction and activation. The clinical trials targeting NSCLC (KRAS G12C and EGFR T790M) will be the 1st ever application of such an approach in humans. Molecules are ready for IND enabling studies and entry into the clinic in 2022.
Felicitex seeks $30M series A investment and biotech and/or pharma partners.